John Eikelboom

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Am J Hematol 87:S100-7. 2012
  2. ncbi Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, L9K 1H8, Canada
    Chest 141:e89S-119S. 2012
  3. ncbi The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    BMC Cardiovasc Disord 8:24. 2008
  4. ncbi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
  5. ncbi Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
    John W Eikelboom
    Thrombosis Service, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 114:774-82. 2006
  6. ncbi Duration of red cell storage before transfusion and in-hospital mortality
    John W Eikelboom
    Department of Medicine, McMaster University, Ontario, Canada
    Am Heart J 159:737-743.e1. 2010
  7. ncbi Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
    John W Eikelboom
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada L8L 2X2
    Am Heart J 159:348-353.e1. 2010
  8. ncbi Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials
    John W Eikelboom
    Thromboembolism Unit, Hamilton General Hospital, Hamilton, Ontario, L8L 2X2, Canada
    Circulation 120:2006-11. 2009
  9. ncbi Aspirin resistance and its implications in clinical practice
    John Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    MedGenMed 7:76. 2005
  10. ncbi Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial
    J W Eikelboom
    Department of Medicine, HGH McMaster Clinic, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 3:2649-55. 2005

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Am J Hematol 87:S100-7. 2012
    ....
  2. ncbi Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, L9K 1H8, Canada
    Chest 141:e89S-119S. 2012
    ....
  3. ncbi The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    BMC Cardiovasc Disord 8:24. 2008
    ..B-vitamin supplements reduce tHcy and improve endothelial function in short term trials, but the long-term effects of the treatment on vascular structure and function are unknown...
  4. ncbi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
    ..The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial...
  5. ncbi Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
    John W Eikelboom
    Thrombosis Service, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 114:774-82. 2006
    ..The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not known to what extent bleeding determines clinical outcome...
  6. ncbi Duration of red cell storage before transfusion and in-hospital mortality
    John W Eikelboom
    Department of Medicine, McMaster University, Ontario, Canada
    Am Heart J 159:737-743.e1. 2010
    ..The objective of the study was to examine the association between duration of pretransfusion storage of red cells and in-hospital mortality...
  7. ncbi Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
    John W Eikelboom
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada L8L 2X2
    Am Heart J 159:348-353.e1. 2010
    ..Apixaban may be an attractive alternative to ASA for prevention of stroke in patients with AF who cannot or will not take a VKA...
  8. ncbi Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials
    John W Eikelboom
    Thromboembolism Unit, Hamilton General Hospital, Hamilton, Ontario, L8L 2X2, Canada
    Circulation 120:2006-11. 2009
    ....
  9. ncbi Aspirin resistance and its implications in clinical practice
    John Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    MedGenMed 7:76. 2005
    ....
  10. ncbi Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial
    J W Eikelboom
    Department of Medicine, HGH McMaster Clinic, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 3:2649-55. 2005
    ....
  11. ncbi Duration of anticoagulant therapy for venous thromboembolism
    Nina C Raju
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Med J Aust 190:659-60. 2009
    ..The risk of bleeding, as well as patient preferences, must be considered when deciding duration of warfarin therapy...
  12. ncbi Monitoring unfractionated heparin with the aPTT: time for a fresh look
    John W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:547-52. 2006
    ..However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies...
  13. ncbi Selective factor Xa inhibition for thromboprophylaxis
    John W Eikelboom
    McMaster University, Hamilton, ON, Canada
    Lancet 372:6-8. 2008
  14. ncbi Guidelines for anticoagulant use in acute coronary syndromes
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, Ont, Canada, L8L 2X2
    Lancet 371:1559-61. 2008
  15. ncbi Combined antiplatelet and anticoagulant therapy: clinical benefits and risks
    J W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, ON, Canada
    J Thromb Haemost 5:255-63. 2007
    ..Whether the benefits of triple therapy outweigh the risks in patients with atrial fibrillation and coronary stents requires evaluation in randomized trials...
  16. ncbi Apixaban in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 364:806-17. 2011
    ..Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients...
  17. ncbi Beyond unfractionated heparin and warfarin: current and future advances
    Jack Hirsh
    Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
    Circulation 116:552-60. 2007
  18. ncbi Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial
    Jeff S Healey
    Population Health Research Institute, McMaster University, Hamilton, Canada
    Circulation 126:343-8. 2012
    ..Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required...
  19. ncbi Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    Stuart J Connolly
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 118:2029-37. 2008
    ..This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy...
  20. ncbi Oral anticoagulant and antiplatelet therapy and peripheral arterial disease
    Sonia Anand
    McMaster University, Hamilton, ON, Canada
    N Engl J Med 357:217-27. 2007
    ..Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear...
  21. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  22. ncbi New anticoagulants for atrial fibrillation
    Magdalena Sobieraj-Teague
    McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 35:515-24. 2009
    ..A new vitamin K antagonist (ATI-5923) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial. None of the new agents have as yet been approved for clinical use...
  23. ncbi Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation
    Jeff S Healey
    Population Health Research Institute, Hamilton, Ontario, Canada
    Can J Cardiol 29:224-8. 2013
    ..This study sought to determine the prevalence and predictors of pacemaker-detected AF and to document current oral anticoagulant use...
  24. ncbi Aspirin resistance: does it exist and is it an important clinical problem?
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital
    Clin Adv Hematol Oncol 4:268-70. 2006
  25. ncbi New oral anticoagulants: not quite there yet
    Ganesan Karthikeyan
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Pol Arch Med Wewn 119:53-8. 2009
    ..In this review, we attempt to provide a balanced perspective on the relative merits and demerits of the new, orally active anticoagulants, and speculate on the future of these agents in clinical practice...
  26. ncbi Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes
    Ahmed Krimly
    Terrence Donnelly Heart Centre, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Cardiol 27:711-5. 2011
    ....
  27. ncbi Challenges of establishing new antithrombotic therapies in atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 116:449-55. 2007
  28. ncbi New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010
    Luciana Armaganijan
    Department of Medicine, Cardiology Division, Arrhythmia Service, McMaster University, HHSC, David Braley CVSRI, Hamilton, Ontario, Canada
    Adv Ther 26:1058-71. 2009
    ..This review focuses on new antithrombotic therapies for stroke prevention in patients with AF...
  29. ncbi Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
    Nina C Raju
    Thrombosis Service, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L2X2, Canada
    Nat Clin Pract Cardiovasc Med 5:766-80. 2008
    ..The nonthienopyridine P2Y(12) inhibitors AZD6140 and cangrelor are presently being evaluated in phase III, randomized, controlled trials...
  30. ncbi Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6
    Ganesan Karthikeyan
    Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada
    Expert Rev Cardiovasc Ther 7:241-9. 2009
    ..This clinical trial report discusses the findings of these two pivotal trials...
  31. ncbi Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators
    Marlene Robinson
    Department of Medicine, McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
    Pacing Clin Electrophysiol 32:378-82. 2009
    ..Low-molecular-weight heparin (LMWH) is often used; however, wound hematoma is a common complication...
  32. ncbi Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials
    John W Eikelboom
    General Division, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 112:3855-67. 2005
    ..These data suggest that LMWH should be the preferred antithrombin in this setting...
  33. ncbi New antithrombotic agents--insights from clinical trials
    Jeremy S Paikin
    Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada
    Nat Rev Cardiol 7:498-509. 2010
    ..In this article, we review these new antithrombotic agents and provide plausible explanations for the results of phase III randomized controlled trials of these drugs...
  34. ncbi Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease
    Magdalena Sobieraj-Teague
    Hamilton Health Sciences, McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Future Cardiol 6:289-99. 2010
    ....
  35. ncbi Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    ..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...
  36. ncbi Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review
    MARTIN J O'DONNELL
    McMaster University, Ontario, Canada
    Stroke 39:1638-46. 2008
    ....
  37. ncbi Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial
    Shamir R Mehta
    Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Am Coll Cardiol 50:1742-51. 2007
    ..This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial...
  38. ncbi Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    Guillaume Pare
    Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 363:1704-14. 2010
    ....
  39. ncbi Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes
    James D Douketis
    Department of Medicine, McMaster University, and St Joseph s Hospital, Hamilton, Ontario, Canada L8N 4A6
    Arch Intern Med 162:1465-71. 2002
    ....
  40. ncbi Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents
    Jeremy S Paikin
    McMaster University, Hamilton, Ontario, Canada
    Med J Aust 192:487-8. 2010
    ..Decisions regarding the use of triple therapy should take into account the balance between thromboembolism and bleeding risk in individual patients...
  41. ncbi Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
    Shamir R Mehta
    McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 118:2038-46. 2008
    ..Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported...
  42. ncbi Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction
    Shoaib Amlani
    Department of Medicine, McMaster University, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    J Thromb Thrombolysis 30:434-40. 2010
    ..Therapies that maintain efficacy while reducing bleeding and that reduce the risk of death in patients who develop bleeding are needed...
  43. ncbi Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes
    Shamir R Mehta
    Department of Medicine, Mc Master University, Hamilton Health Sciences, Hamilton, ON, Canada
    Can J Physiol Pharmacol 83:98-103. 2005
    ..Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management...
  44. ncbi Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends
    Jack C J Sun
    Division of Cardiac Surgery, McMaster University, Hamilton, ON, Canada
    Lancet 374:565-76. 2009
    ....
  45. ncbi The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies
    Jack C J Sun
    Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Eur Heart J 29:1057-71. 2008
    ..To obtain estimates of the efficacy and safety of pre-operative aspirin in patients undergoing coronary artery bypass grafting (CABG)...
  46. ncbi Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency
    Wendy Lim
    McMaster University and Hamilton General Hospital, Hamilton, Ontario, Canada
    Ann Intern Med 144:673-84. 2006
    ....
  47. ncbi Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial
    Jon David R Schwalm
    Department of Medicine, Division of Cardiology, Hamilton Health Sciences and McMaster University, 5th Floor, McMaster Clinic, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    J Thromb Thrombolysis 30:127-32. 2010
    ..The purpose of this study is to assess the feasibility of evaluating the added benefit and safety of triple therapy (TT-warfarin, ASA, and clopidogrel) versus dual therapy (DT-ASA and clopidogrel) in patients at risk of LVT post aSTEMI...
  48. ncbi Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study
    Jack C J Sun
    Division of Cardiac Surgery, McMaster University, Hamilton, Canada
    Am Heart J 160:1178-84. 2010
    ..We performed a pilot study measuring safety and efficacy outcomes of aspirin and clopidogrel therapy after CABG...
  49. ncbi American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 135:513-20. 2009
    ....
  50. ncbi Genetic determinants of dabigatran plasma levels and their relation to bleeding
    Guillaume Pare
    MSc, FRCPC, Population Health Research Institute, Hamilton Health Sciences and McMaster University, David Braley Cardiac Vascular and Stroke Research Institute, 237 Barton St E, Room C3 103, Hamilton, ON, Canada L8L 2X2
    Circulation 127:1404-12. 2013
    ..We hypothesized that genetic variants could contribute to interindividual variability in blood concentrations of the active metabolite of dabigatran etexilate and influence the safety and efficacy of dabigatran...
  51. ncbi Platelet function testing: quality assurance
    Catherine P M Hayward
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 33:273-82. 2007
    ..Quality assurance issues relevant to testing platelet function are reviewed in this article, with a focus on their application to established and to new and emerging tests...
  52. ncbi Nonbleeding complications of unfractionated and low-molecular weight heparins
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Adv Hematol Oncol 5:871-3. 2007
  53. ncbi Management of antiphospholipid antibody syndrome: a systematic review
    Wendy Lim
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    JAMA 295:1050-7. 2006
    ..The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies...
  54. ncbi Inherited thrombophilia and pregnancy associated venous thromboembolism
    Wendy Lim
    Department of Medicine, McMaster University, St Joseph's Hospital, Canada
    BMJ 334:1318-21. 2007
  55. ncbi Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
    John W Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    Circulation 118:1705-12. 2008
    ....
  56. ncbi Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients
    Robby Nieuwlaat
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Thromb Res 125:e128-31. 2010
    ..We assessed to what extent generalist and specialist physicians use evidence-based methods for warfarin maintenance dosing...
  57. ncbi Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials
    Daniel J Quinlan
    King's College Hospital, London, United Kingdom
    Ann Intern Med 140:175-83. 2004
    ..CONCLUSIONS: Fixed-dose low-molecular-weight heparin treatment appears to be as effective and safe as dose-adjusted intravenous unfractionated heparin for the initial treatment of nonmassive pulmonary embolism...
  58. ncbi Will prasugrel supersede clopidogrel for acute coronary syndromes?
    Graeme J Hankey
    Med J Aust 188:381-2. 2008
  59. ncbi Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
    ..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population...
  60. ncbi Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks
    Graeme J Hankey
    Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia
    Neurology 64:1117-21. 2005
    ....
  61. ncbi Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Perth, West Australia
    Circulation 110:744-9. 2004
    ..The number of patients enrolled in randomized trials to date is modest, and further evaluation of the efficacy and safety of thrombolytic therapy for the treatment of high-risk patients with acute pulmonary embolism appears warranted...
  62. ncbi Antiplatelet agents in acute coronary syndromes
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital and Department of Medicine, University of Western Australia, Crawley, WA, Australia
    Semin Vasc Med 3:403-14. 2003
    ....
  63. ncbi The beginning of the end of warfarin?
    John W Eikelboom
    Med J Aust 180:549-51. 2004
  64. ncbi Thromboprophylaxis practice patterns in two Western Australian teaching hospitals
    John W Eikelboom
    Department of Hematology, Royal Perth Hospital, Wellington Street, Perth, WA, 6001 Australia
    Haematologica 89:586-93. 2004
    ..Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines...
  65. ncbi Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital, Perth, Australia
    Expert Opin Pharmacother 5:493-503. 2004
    ..g., > 20%/year). The combination of clopidogrel and aspirin should be considered in patients with non-ST-segment elevation acute coronary syndrome or undergoing percutaneous coronary intervention...
  66. ncbi Aspirin resistance
    Graeme J Hankey
    BMJ 328:477-9. 2004
  67. ncbi Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia
    Am J Cardiovasc Drugs 4:57-67. 2004
    ....
  68. ncbi Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
    Graeme J Hankey
    Stroke Unit, Royal Perth Hospital, 197 Wellington Street Perth, Australia 6001
    Stroke 35:389-91. 2004
  69. ncbi Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia
    ANZ J Surg 73:826-9. 2003
    ..These data should prompt the implementation of effective strategies to improve thromboprophylaxis practice patterns in high-risk orthopaedic patients...
  70. ncbi Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes
    Paul Cherian
    Department of Medicine, University of Western Australia, Perth, Australia
    Stroke 34:2132-7. 2003
    ..Persistent elevated blood concentrations of PDM may be a marker of increased risk of ischemic stroke...
  71. ncbi Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy?
    John W Eikelboom
    Med J Aust 179:68-9. 2003
    ..The recently released PREVENT trial provides some answers...
  72. ncbi Antiplatelet drugs
    Graeme J Hankey
    Royal Perth Hospital, 197 Wellington Street, Perth, WA 6001, Australia
    Med J Aust 178:568-74. 2003
    ....
  73. ncbi Aspirin resistance: a new independent predictor of vascular events?
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Wellington Street, Perth, WA 6001, Australia
    J Am Coll Cardiol 41:966-8. 2003
  74. ncbi Low molecular weight heparins and heparinoids
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, GPO Box X2213, Perth, WA 6001, Australia
    Med J Aust 177:379-83. 2002
    ..The heparinoid danaparoid sodium is effective for the treatment of heparin-induced thrombocytopenia...
  75. ncbi Venous thromboembolism: diagnosis and management of deep venous thrombosis
    Wai Khoon Ho
    Royal Perth Hospital, Perth, WA
    Med J Aust 182:476-81. 2005
    ..The risk of recurrence is highest in people with recurrent unprovoked DVT or chronic predisposing factors (eg, cancer) who require indefinite anticoagulant treatment...
  76. ncbi Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?
    Wai Khoon Ho
    Centre for Clinical Research Excellence, Department of Neurology and Department of Haematology, Royal Perth Hospital, Australia and School of Medicine and Pharmacology, University of Western Australia, Australia
    Blood Coagul Fibrinolysis 15:129-30. 2004
  77. ncbi Who is (still) getting HIT?
    Theodore E Warkentin
    Chest 131:1620-2. 2007
  78. ncbi Latest medical treatment strategies for venous thromboembolism
    Simon J McRae
    The Queen Elizabeth Hospital, Institute of Medical and Veterinary Sciences, Department of Haematology Oncology, 28 Woodville Rd, Woodville 5011, Adelaide, South Australia, Australia
    Expert Opin Pharmacother 8:1221-33. 2007
    ....
  79. ncbi Anticoagulation for venous thromboembolism
    John W Eikelboom
    BMJ 334:645. 2007
  80. ncbi Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)
    Huyen Tran
    Department of Clinical Haematology, Monash Medical Centre, Victoria, Australia
    Vasc Health Risk Manag 2:379-87. 2006
    ..Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI...
  81. ncbi Aspirin resistance
    Huyen A Tran
    Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria, Australia
    Thromb Res 120:337-46. 2007
    ....
  82. ncbi Guidelines for the management of acute coronary syndromes 2006
    John W Eikelboom
    Med J Aust 186:101; discussion 101-2. 2007
  83. ncbi A replacement for warfarin: the search continues
    John W Eikelboom
    Circulation 116:131-3. 2007
  84. ncbi The tissue factor pathway in ischemic stroke
    Murray J Adams
    Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University, Perth, Australia
    Blood Coagul Fibrinolysis 17:527-32. 2006
    ....
  85. ncbi Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction
    Peter Sleight
    N Engl J Med 354:2830-1; author reply 2831-2. 2006
  86. ncbi Bone marrow biopsy in thrombocytopenic or anticoagulated patients
    John W Eikelboom
    Br J Haematol 129:562-3. 2005
  87. ncbi Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    Andrew McQuillan
    N Engl J Med 346:1589-90; author reply 1589-90. 2002
  88. ncbi Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
    John W Eikelboom
    Department of Medicine, Thrombosis and Haemophilia Unit, University of Western Australia, Royal Perth Hospital, Australia
    Drugs 62:1839-52. 2002
    ....
  89. ncbi Venous thromboembolism: diagnosis and management of pulmonary embolism
    Cindy H Lee
    Department of Haematology, Royal Perth Hospital, Perth, WA, Australia
    Med J Aust 182:569-74. 2005
    ....
  90. ncbi Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia
    Julie H Crawford
    Royal Perth Hospital, Perth, Western Australia, Australia
    Eur J Haematol 69:315-7. 2002
    ....
  91. ncbi Clinical usefulness of plasma homocysteine in vascular disease
    Graeme J Hankey
    Department of Neurology, Royal Perth Hospital, Wellington Street, Perth, Western Australia, 6001
    Med J Aust 181:314-8. 2004
    ..There is currently insufficient evidence to recommend routine screening and treatment of high tHcy concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease...
  92. ncbi Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications
    Paul E Norman
    School of Surgery and Pathology, Fremantle Hospital, PO Box 480, Fremantle, WA 6959, Australia
    Med J Aust 181:150-4. 2004
    ..Patients with PAD require medical management to prevent future coronary and cerebral vascular events. There are currently insufficient data to recommend routine population screening for asymptomatic PAD using the ABPI...
  93. ncbi Aspirin resistance
    Graeme J Hankey
    Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
    Lancet 367:606-17. 2006
    ..Potential mechanisms of aspirin resistance can then be explored and treatments assessed...
  94. ncbi Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence, University of Western Australia, Perth
    Arch Intern Med 166:729-36. 2006
    ..These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE...
  95. ncbi Venous thromboembolism in travellers: can we identify those at risk?
    Andrew D McQuillan
    Department of Haematology, Royal Perth Hospital, Perth, Australia, and School of Medicine and Pharmacology, University of Western Australia
    Blood Coagul Fibrinolysis 14:671-5. 2003
    ..Whether patients with known risk factors for venous thromboembolism prior to travel should be targeted with specific thromboprophylaxis requires randomized evaluation...
  96. ncbi The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality
    Magdalena Sobieraj-Teague
    Department of Haematology, Flinders Medical Centre, Adelaide, Australia
    Curr Opin Cardiol 23:327-34. 2008
    ....
  97. ncbi Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant
    Jim Thom
    Coagulation and Thrombosis Unit, Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia
    Blood Coagul Fibrinolysis 15:353-7. 2004
    ..60, P < 0.0001) but there was no correlation in the presence of lupus anticoagulant (r = -0.13, P = 0.68). Our results suggest that the prdRVVT is not suitable for monitoring warfarin therapy in patients with lupus anticoagulant...
  98. ncbi Antithrombotic treatment for peripheral arterial disease
    Daniel G Hackam
    Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Canada
    Heart 93:303-8. 2007
    ..In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis...
  99. ncbi ESPRIT trial
    John W Eikelboom
    Lancet 368:447; author reply 449. 2006
  100. ncbi Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction
    John K French
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiovasc Drugs 4:107-15. 2004
    ..The major benefit of direct thrombin inhibitors appears to be in patients undergoing PCI, particularly after STEMI...
  101. ncbi The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia
    Wai Khoon Ho
    Department of Haematology, Austin and Repatriation Medical Centre, Melbourne, Vic, Australia
    Med J Aust 189:144-7. 2008
    ....